Dassault Systemes

Hanmi Selects the Medidata Clinical Cloud for Faster Data Capture and Better Operational Oversight of Clinical Trials

Press Release
March 19, 2013

03/19/2013

Korean Pharma Implements Medidata Rave for Improved
Site Productivity and Enhanced Data Management

NEW YORK, N.Y. and SEOUL, KOREA – March 19, 2013 – The Medidata Solutions (NASDAQ: MDSO) platform has been selected by Hanmi Pharmaceutical Co., Ltd., a leading Korean pharmaceutical company, to support data collection and management in Phase I and II oncology clinical trials.

Hanmi's choice of the Medidata Clinical Cloud™ supports the company's wider initiative to improve workflows and productivity while developing new therapies. In particular, Hanmi anticipates that its use of Rave will enhance site productivity through real-time data entry in an intuitive user interface and will also help streamline trials through Rave's timely reporting capabilities and smooth handling of mid-study protocol amendments.

  • Hanmi's commitment to efficiently providing new innovative drugs across a number of therapeutic areas is reinforced by their adoption of the Medidata Clinical Cloud, said Glen de Vries, president, Medidata Solutions. By tapping into the effectiveness of next generation technologies, Hanmi is showing its dedication to safely expedite R&D to help bring drugs to waiting patients faster.

By implementing Rave, the company also anticipates that more timely access to data for analysis will support better trial oversight and more informed and earlier decision making. Additionally, Hanmi anticipates better study start-up through Rave's reusable study assets and its standards-based integration framework that facilitates rapid integrations with other systems to enable data sharing.

  • Medidata's reputation for streamlining clinical trials and enhancing trial decision making was a major factor in our decision to select the Medidata platform, said Jeewoong Son, senior vice president, Hanmi. Medidata's commitment to designing cloud-based solutions that enhance research team productivity through user-friendly interfaces will play a role in driving efficiencies in our drug development programs and reducing the total cost of our clinical development.

Connect with Medidata:

About Hanmi Pharmaceutical Co., Ltd.
Established in 1973, Hanmi Pharmaceuticals now is one of the top 5 pharmaceutical companies in Korea, and has been the most R&D focused company with the highest R&D investment for several years. Hanmi Pharma also has worldwide offices in major countrie